---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-024496"
form_type: "8-K"
ticker: "OGN"
cik: "0001821825"
company_name: "Organon & Co."
filed_at: "2022-02-17T23:59:59+00:00"
generated_at: "2026-06-27T07:08:08.286739+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Organon FY21 rev $6.3B, adj. EPS $6.54; provides FY22 guide rev $6.1-$6.4B, adj. EBITDA margin 34-36%

## Summary
- FY21 revenue $6.3B (-3% as-reported vs 2020); GAAP diluted EPS $5.31; non-GAAP adj. diluted EPS $6.54.
- Q4 revenue $1.604B (-1% YoY); adj. EBITDA margin 34.2% vs 42.2% in prior year.
- Board declared $0.28 quarterly dividend payable March 17, 2022; record date Feb 28.
- FY22 guidance: revenue $6.1-$6.4B; adj. EBITDA margin 34%-36%; interest ~$400M; tax rate 17.5%-19.5%.
- Growth engines (Nexplanon, fertility, biosimilars) grew double digits; 4 business development deals since spin.

## SEC filing metadata
- accession: 0001104659-22-024496
- form_type: 8-K
- ticker: OGN
- cik: 0001821825
- company_name: Organon & Co.
- filed_at: 2022-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821825/000110465922024496/0001104659-22-024496-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821825/000110465922024496/tm227000d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-024496
- JSON: https://secwatch.observer/filing/0001104659-22-024496.json
- Plain text: https://secwatch.observer/filing/0001104659-22-024496.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.